Iwona K Rzepecka
Overview
Explore the profile of Iwona K Rzepecka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1265
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rzepecka I, Tysarowski A, Konopka B, Dansonka-Mieszkowska A, Kupryjanczyk J
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39858051
Background: The phosphoinositide 3-kinase (PI3K) pathway is activated in multiple cancers. However, the significance of encoding the PI3K regulatory subunit, an inhibitor of the PI3K catalytic subunit encoded by ,...
2.
Kalachand R, Stordal B, Madden S, Chandler B, Cunningham J, Goode E, et al.
J Natl Cancer Inst
. 2020 May;
112(12):1190-1203.
PMID: 32413141
Background: BRCA1 methylation has been associated with homologous recombination deficiency, a biomarker of platinum sensitivity. Studies evaluating BRCA1-methylated tubal and ovarian cancer (OC) do not consistently support improved survival following...
3.
Moes-Sosnowska J, Rzepecka I, Chodzynska J, Dansonka-Mieszkowska A, Szafron L, Balabas A, et al.
Cancer Biol Ther
. 2019 Mar;
20(6):843-854.
PMID: 30822218
Objective: DNA repair pathways are potential targets of molecular therapy in cancer patients. The FANCD2, BRIP1, BRCA1/2, and FANCF genes are involved in homologous recombination DNA repair, which implicates their...
4.
Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B, Schildkraut J, et al.
Cancer Res
. 2018 Jul;
78(18):5419-5430.
PMID: 30054336
Large-scale genome-wide association studies (GWAS) have identified approximately 35 loci associated with epithelial ovarian cancer (EOC) risk. The majority of GWAS-identified disease susceptibility variants are located in noncoding regions, and...
5.
Earp M, Tyrer J, Winham S, Lin H, Chornokur G, Dennis J, et al.
PLoS One
. 2018 Jul;
13(7):e0197561.
PMID: 29979793
Epithelial ovarian cancer (EOC) is the fifth leading cause of cancer mortality in American women. Normal ovarian physiology is intricately connected to small GTP binding proteins of the Ras superfamily...
6.
Dansonka-Mieszkowska A, Szafron L, Moes-Sosnowska J, Kulinczak M, Balcerak A, Konopka B, et al.
Oncotarget
. 2018 May;
9(25):17735-17755.
PMID: 29707144
EMSY, a BRCA2-associated protein, is amplified and overexpressed in various sporadic cancers. This is the first study assessing the clinical impact of its expression and polymorphisms on ovarian cancer (OvCa)...
7.
Dixon-Suen S, Nagle C, Thrift A, Pharoah P, Ewing A, Pearce C, et al.
Br J Cancer
. 2018 Mar;
118(8):1123-1129.
PMID: 29555990
Background: Observational studies suggest greater height is associated with increased ovarian cancer risk, but cannot exclude bias and/or confounding as explanations for this. Mendelian randomisation (MR) can provide evidence which...
8.
Rzepecka I, Szafron L, Stys A, Felisiak-Golabek A, Podgorska A, Timorek A, et al.
Gynecol Oncol
. 2016 Dec;
144(2):369-376.
PMID: 27939982
Objective: TP53 mutation is the most frequent molecular event in BRCA1-associated ovarian carcinomas. TP53 status may be a confounding factor in the evaluation of clinical importance of other proteins. We...
9.
Hampras S, Sucheston-Campbell L, Cannioto R, Chang-Claude J, Modugno F, Dork T, et al.
Oncotarget
. 2016 Aug;
7(43):69097-69110.
PMID: 27533245
Background: Regulatory T (Treg) cells, a subset of CD4+ T lymphocytes, are mediators of immunosuppression in cancer, and, thus, variants in genes encoding Treg cell immune molecules could be associated...
10.
Lisowska K, Olbryt M, Student S, Kujawa K, Cortez A, Simek K, et al.
J Cancer Res Clin Oncol
. 2016 Mar;
142(6):1239-52.
PMID: 27028324
Purpose: Ovarian cancer is typically diagnosed at late stages, and thus, patients' prognosis is poor. Improvement in treatment outcomes depends, at least partly, on better understanding of ovarian cancer biology...